Hemispherx, the company that makes the experimental ME drug Ampligen, applied for approval in Argentina in July of 2012. ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), Argentina’s version of the FDA, generally renders decisions in one year. The company already received approval for a form of interferon called Alferon in Latin American countries (it's approved in the U.S. for genital warts). And ANMAT broadened Alferon's approval this year to include other diseases, including hepatitis C.
Hemispherx's stock price, which had plummeted from $1.10 to 18 cents a share following FDA's refusal to approve the drug for ME at the close of 2012, recently has been edging up, hitting a high of 29 cents today.
.jpg){kind=small}
